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Cardiac arrest in dialysis patients: Approaches to alter an abys- sustaining AMI [3]. About 20% of cardiac deaths are
mal outcome. Cardiac disease is the major cause of death in attributed to AMI [1]. It is difficult to accurately appor-
dialysis patients, accounting for 45% of all-cause mortality. tion the absolute percentage of cardiac death directlySudden cardiac death may be implicated in 60% of these car-
attributable to complications of ischemic heart disease,diac deaths in dialysis patients. The combination of obstructive
as a host of factors, including obstructive coronary arterycoronary artery disease, electrolyte shifts (in hemodialysis pa-
tients), left ventricular hypertrophy, and abnormal myocardial disease (CAD), contribute to the demise of dialysis pa-
ultrastructure and function may contribute to the vulnerability tients.
of ESRD patients to sudden death.
Sudden cardiac death may be implicated in 60% ofIn this review, the epidemiology of cardiac arrest in dialysis
all cardiac deaths in dialysis patients. In the USRDSpatients is presented, including the high lethality associated
with cardiac arrest. Clinical strategies to reduce the likelihood database, “cardiac arrest, cause unknown” accounted
of fatal cardiac arrest include the identification of high-risk for 47% of all cardiac deaths, and another 13% were
patients, alteration of dialysis prescription to avoid large vol- attributed to arrhythmia [4]. Besides obstructive CAD,
ume and electrolyte shifts, and reduction of myocardial isch-
factors contributing to the peculiar vulnerability ofemic burden. Implantable cardioverter defibrillators may po-
ESRD patients to sudden death include left ventriculartentially reduce the risk of fatal cardiac arrest in dialysis
patients and improve long-term cardiac survival. hypertrophy, electrolyte shifts in hemodialysis patients,
and abnormalities in myocardial ultrastructure and func-
tion, including endothelial dysfunction (worse in diabet-
ics), interstitial fibrosis, decreased perfusion reserve, and
diminished ischemia tolerance [5–8]. (The developmentTHE BURDEN OF CARDIAC DISEASE IN
of left ventricular hypertrophy may be promoted by ane-DIALYSIS PATIENTS
mia and vascular noncompliance. Attempts to retard the
Dialysis patients are a high-risk group for all-cause development of LVH should ideally include measures
death. The death rate for all US dialysis patients between aimed at arresting or reversing the development of ath-
1996 and 1998 was 231/1000 patient years [1]. Cardiac erosclerosis in the vasculature and maintenance of
disease is the major cause of death in dialysis patients, “physiologic” loading conditions).
accounting for approximately 45% of all-cause mortality
[1]. The burden of cardiovascular disease in ESRD pa-
tients in the US is projected to increase, as the greatest CARDIAC ARREST
increase in treated ESRD has occurred in patients with Cardiac arrest is a devastating clinical event in dialysis
the highest risk for cardiovascular disease, older patients, patients. We have recently analyzed the outcome of a
and those with diabetic nephropathy. cohort of incident dialysis patients (1995 to 99) surviving
Dialysis patients sustaining acute myocardial infarction at least one year after dialysis initiation [3]. In our study,
(AMI) suffer poor long-term survival, with a two-year Group 1 patients (N 130,379) had diabetes as the cause
mortality of 74% for AMI occurring between 1990 and of ESRD, Group 2 patients (N  19,411) had diabetes
1995 [2], and this outcome has not changed in our most as a comorbid condition at dialysis initiation (but not
recent analysis of incident (1995 to 1999) dialysis patients the primary cause of ESRD), Group 3 patients (N 
25,351) were reported to have diabetes (not previously
identified) by claims data in the year after dialysis initia-Key words: end-stage renal disease, coronary artery disease, defibrilla-
tor, sudden death. tion, and Group 4 patients (N  120,772) did not have
diabetes. Figure 1 shows the estimated cardiac arrest 2003 by the International Society of Nephrology
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Fig. 1. Event rates and adjusted event-free
survival: cardiac arrest.
event rates. For the entire group, at year one, the cardiac that will reduce the risk of the occurrence of cardiac
arrest. The second is to employ therapies that improvearrest rate was 93 events/1000 patient years, rising to 164
events/1000 patient years at year four. Diabetic ESRD the likelihood of surviving a cardiac arrest.
patients comprise a strikingly high-risk group for cardiac
arrest, ranging from 110 events/1000 patient years at year
CAN WE IDENTIFY THE HIGH-RISKone to 208 events/1000 patient years at year four. Even
DIALYSIS PATIENT?the lowest risk group (nondiabetic group 4 patients) had
The identification of ESRD patients at risk for cardiaca cardiac arrest rate of 70/1000 patient years at year one,
arrest is a logical first step, provided that it is possiblerising to 131 events/1000 patient years at year four. In
to meaningfully risk stratify ESRD patients. Viewedpatients with diabetic ESRD, cardiac arrest would be
from the perspective of the general population, even theprojected in 21% of patients at two years, 43% at four
lowest risk nondiabetic Group 4 patients would still beyears, and 61% at five years compared with the nondia-
conventionally considered to be a high-risk populationbetic patients with cardiac arrest in 14% at two years,
for cardiac arrest. It may be possible to identify a subset31% at four years, and 49% at five years. For the entire
of dialysis patients at the highest risk for death withstudy cohort, cardiac arrest was estimated to occur in
outpatient testing for the presence of increased serum18% of patients at two years, 37% at four years, and
cardiac troponin I and troponin T, as both appear to53% at five years. These event rates are of great clinical
prospectively identify dialysis patients at increased riskconcern, as they suggest that the hazard of cardiac arrest
for mortality [9] (abstract; Herzog CA et al, J Am Socafter dialysis initiation is not uniform over time, but
Nephrol 11:272A, 2000). Electrocardiographic markersincreases with older patients. These observational data
for susceptibility to sudden death may also have a rolesupport the concept that ESRD is a primary promoter
in this population. Prolonged Q-T dispersion, a measureof cardiovascular disease, and specifically, of increasing
of heterogeneity of ventricular repolarization, has beenrisk for sudden cardiac death.
linked with an increased risk of sudden death in nondial-The catastrophic outcome of cardiac arrest is graphi-
ysis patients, and it may be prolonged, particularly aftercally demonstrated in Fig. 2, which shows the survival
hemodialysis [10, 11]. Autonomic dysfunction (as as-of those study patients sustaining a cardiac arrest. For
sessed by abnormal heart rate variability) may be athe entire cohort, the 30-day survival was 32%, and was
marker for increased sudden death risk in ESRD patients15% at one year. Patients with diabetic nephropathy
[12]; abnormal heart rate variability in non–renal post-fared slightly worse, with a 13% one-year survival, com-
AMI patients has been shown to be a predictor of cardiacpared with 17% for the nondiabetic patients. Clearly,
death. Although ventricular extrasystoles are common incardiac arrest is a pre-eminent concern in dialysis pa-
dialysis patients, they are not good predictors of cardiactients, because it is a common clinical event characterized
death [13].by a high degree of lethality. There are two distinct, but
It is plausible that the nonphysiologic nature of con-complementary, strategies for dealing with cardiac arrest
in ESRD patients. The first is to implement measures ventional thrice-weekly hemodialysis schedules contrib-
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Fig. 2. Survival after cardiac arrest.
utes to excess sudden cardiac death. Using USRDS data, the use of beta-blocker therapy in dialysis patients is
associated with a reduction in mortality risk, based onBleyer et al [14] have reported nearly a 50% increased
a recent paper by Foley et al [18]. The value of primaryfrequency of sudden and cardiac death on Monday (for
anti-arrhythmic agents, such as amiodarone, is unknown.patients dialyzing Monday, Wednesday, and Friday), and
It is difficult to ignore the data of Bleyer et al and Karniksimilar trends on Tuesday (for patients on a Tuesday,
on the potential contribution of hemodialysis (and es-Thursday, Saturday schedule). Karnik et al [15], using
pecially low-potassium dialysate) to sudden death. Adata from Fresenius Medical Care North America, re-
randomized trial comparing conventional to frequentported a cardiac arrest rate of 7 per 100,000 hemodialysis
long-duration dialysis is sorely needed. The consistentsessions. Monday was the most likely day for cardiac
maintenance of relative euvolemia conceivably mightarrests. Based on a case-control comparison, patients
have other benefits favorably impacting long-term sur-with cardiac arrest were nearly twice as likely to have
vival, such as maintenance of normotensive blood pres-been dialyzed against a 0 or 1.0 mEq/L potassium dialy-
sures and decreased left ventricular hypertrophy.sate on the day of cardiac arrest. The 48-hour mortality
A second approach is to reduce the lethality of cardiacof the 400 cardiac arrest patients in this study was 60%.
arrest. There are currently no published data on long-Long-term survival after cardiopulmonary resuscitation
term survival of ESRD patients following implantationis strikingly poor: 92% in-hospital death and 97% 6-month
of percutaneous cardioverter defibrillators (PCDs), andmortality in 74 patients, reported by Moss et al [16], and
this is a current area of investigation for this author.100% in-hospital mortality in 24 patients in the series of
With their high cardiac arrest risk and abysmal survivalLai et al [17].
after cardiac arrest, ESRD patients are a logical popula-
tion for studies on the efficacy of PCDs. Despite my
CAN WE ALTER THE ABYSMAL OUTCOME? interest (and companies that manufacture PCDs) in this
There are several therapeutic strategies for reducing approach, I believe a note of caution is prudent, as the
the risk of cardiac arrest in ESRD patients. All measures issue of competing risk of morbidity and mortality (due
aimed at successfully reducing the total burden and like- to other causes) will repeatedly surface in dialysis pa-
lihood of acute myocardial ischemia might be beneficial. tients being subjected to cardiac interventions. Having
These could include coronary revascularization (pro- a patient suffer a massive stroke after surviving a cardiac
vided the periprocedural mortality risk and necessity of arrest (treated successfully by a PCD) might not be
repeat revascularization is sufficiently low), anti-platelet viewed as a therapeutic triumph.
Dialysis patients are at extraordinary risk for suddenagents, statins, and beta-blocker therapy. Interestingly,
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approaches exist to reduce the risk of cardiac arrest in 1998
6. Amann K, Ritz E: Cardiac disease in chronic uremia: Pathophysi-these patients. A randomized clinical trial on the efficacy
ology. Adv Ren Replace Ther 4:212–224, 1997of percutaneous cardioverter defibrillators for reduction
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of mortality in dialysis patients would be a worthy inter- renal failure. Adv Nephrol Necker Hosp 27:85–103, 1997
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